



Corporate press release

Norgine and Alfa Wassermann Further Cement their Business Relationship

Norgine is delighted to announce that it has signed a further deal with Alfa Wassermann which gives it the rights to market XIFAXAN® (rifaximin- α) in the Middle East. Norgine has acquired marketing rights in nine countries including Egypt and Saudi Arabia.

Norgine's CEO Peter Stein commented that 'Norgine is delighted to extend its current relationship with Alfa Wassermann and we look forward to expanding our business in these territories. This is an important step in the development of Norgine's operations in the Middle East and North Africa'

Alfa Wassermann's CEO, Stefano Golinelli, praising the accord, has added that 'Norgine's marketing of our rifaximin- α , one of the most important fruits of the Alfa Wassermann's R&D activities in the Middle East, will provide an additional important territorial coverage for rifaximin- α which is already available in almost all the most important markets under different trade-marks (Normix®, Xifaxan®, Spiraxin®, Lormyx®, Flonorm® and others) either directly from Alfa Wassermann and its own subsidiaries or through highly qualified licence partners like Norgine.'

Ends

Notes to editor.

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a presence in all the major European markets. In 2009 Norgine's net product sales were €254 million, the 23rd year of double-digit growth at constant exchange rates. The company employs over 1,000 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in various markets in its key therapeutic areas e.g., MOVICOL® for the treatment of constipation and faecal impaction, MOVIPREP® a new generation of bowel cleansing preparation, KLEAN-PREP® for bowel preparation prior to colonoscopy, XIFAXAN® for the treatment of traveller's diarrhoea and ORAMORPH® for the treatment of moderate to severe pain associated with cancer.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, Wales and Dreux in France.

www.norgine.com

Alfa Wassermann is a privately owned Pharmaceutical Enterprise headquartered in Bologna – Italy with subsidiaries in several European and non-European countries. In 2009 Alfa Wassermann has totalled €281 million in revenues and has employed over 1,200 people.

Alfa Wassermann's growth has been provided by a mix of new products market introduction and geographical expansion where over two third of the revenue contribution comes from original, proprietary, products sold directly or through licensing partners and distributors in over 60 different markets.

www.alfawassermann.it

For further information, please contact:

Julie Hornby Winfield. Global Corporate Communications Manager

T: +44 (0)1895 826642

E: jhornbywinfield@norgine.com